Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11324303 | 0.84 | PER2 (0.41) | L3MBTL3L3MBTL1NPY5RALDH1A1 | |
| SCHEMBL3068209 | 0.79 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL20040023 | 0.76 | L3MBTL1 (0.42) | L3MBTL3L3MBTL1NPY5RALDH1A1LMNA | |
| SCHEMBL1182635 | 0.76 | GPR119 (0.51) | — | |
| SCHEMBL799397 | 0.75 | HTR2A (0.54) | HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL26683504 | 0.74 | L3MBTL3 (0.40) | L3MBTL3HTR2AHTR2CL3MBTL1NPY5R | |
| SCHEMBL14295197 | 0.73 | — | — | |
| SCHEMBL16368849 | 0.73 | HTR2A (0.38) | HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL21422793 | 0.73 | HTR2A (0.39) | HTR2AHTR2CL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4566681 | 0.71 | CYP4F2 (0.35) | HTR2AHTR2CL3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190815-B1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| CN-101861302-A | Pyrrolidine aryl-ether as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2010-10-13 | — | — | CN | disclosed |
| US-7812021-B2 | Pyrrolidine aryl-ether as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2190815-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2009024502-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRD1, OPRK1 | L3MBTL3 1968/4885HTR2A 146/4885HTR2C 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.